Tralokinumab-ldrm is approved for the treatment of moderate-to-severe AD in adult and adolescent patients 12 years and older in the European Union, Canada, Great Britain, the United Arab Emirates, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results